Wall Street brokerages expect that Acorda Therapeutics Inc (NASDAQ:ACOR) will report earnings per share of $1.09 for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Acorda Therapeutics’ earnings, with the lowest EPS estimate coming in at $0.76 and the highest estimate coming in at $1.44. Acorda Therapeutics posted earnings per share of $0.05 in the same quarter last year, which suggests a positive year over year growth rate of 2,080%. The firm is scheduled to report its next quarterly earnings report before the market opens on Thursday, February 15th.
According to Zacks, analysts expect that Acorda Therapeutics will report full year earnings of $1.81 per share for the current year, with EPS estimates ranging from $1.42 to $2.59. For the next year, analysts expect that the business will report earnings of $0.97 per share, with EPS estimates ranging from $0.10 to $2.97. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Acorda Therapeutics.
Several brokerages have weighed in on ACOR. Raymond James Financial lowered Acorda Therapeutics from a “market perform” rating to an “underperform” rating and increased their target price for the stock from $7.00 to $13.00 in a research report on Thursday, November 16th. Zacks Investment Research lowered Acorda Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. JPMorgan Chase & Co. set a $24.00 target price on Acorda Therapeutics and gave the stock a “hold” rating in a research report on Tuesday, October 31st. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 target price (down from $34.00) on shares of Acorda Therapeutics in a research report on Wednesday, January 17th. Finally, Oppenheimer began coverage on Acorda Therapeutics in a research report on Thursday, November 9th. They issued a “market perform” rating and a $27.00 target price on the stock. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $21.35.
In related news, insider David Lawrence sold 31,000 shares of the firm’s stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $27.58, for a total transaction of $854,980.00. Following the completion of the transaction, the insider now owns 5,275 shares of the company’s stock, valued at $145,484.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Burkhard Blank sold 11,050 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $20.53, for a total value of $226,856.50. Following the transaction, the insider now directly owns 33,150 shares of the company’s stock, valued at approximately $680,569.50. The disclosure for this sale can be found here. Corporate insiders own 7.90% of the company’s stock.
A number of hedge funds have recently made changes to their positions in ACOR. State Street Corp boosted its stake in Acorda Therapeutics by 52.4% during the second quarter. State Street Corp now owns 2,476,033 shares of the biopharmaceutical company’s stock valued at $48,783,000 after buying an additional 851,290 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Acorda Therapeutics by 29.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,372,868 shares of the biopharmaceutical company’s stock valued at $46,745,000 after purchasing an additional 541,418 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Acorda Therapeutics by 306.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 534,956 shares of the biopharmaceutical company’s stock valued at $10,538,000 after purchasing an additional 403,467 shares during the period. Northern Trust Corp boosted its position in shares of Acorda Therapeutics by 65.2% in the 2nd quarter. Northern Trust Corp now owns 897,974 shares of the biopharmaceutical company’s stock valued at $17,690,000 after purchasing an additional 354,304 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Acorda Therapeutics by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 4,308,160 shares of the biopharmaceutical company’s stock valued at $84,871,000 after purchasing an additional 168,571 shares during the period.
Acorda Therapeutics (NASDAQ:ACOR) traded up $0.20 during mid-day trading on Friday, hitting $24.05. The company had a trading volume of 561,803 shares, compared to its average volume of 830,577. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.40 and a current ratio of 2.77. The firm has a market cap of $1,130.00, a price-to-earnings ratio of -19.88 and a beta of 1.63. Acorda Therapeutics has a twelve month low of $13.60 and a twelve month high of $33.00.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.